This page shows the latest MET inhibitor news and features for those working in and with pharma, biotech and healthcare.
The PD-L1 inhibitor met both primary endpoints of overall survival (OS) and progression-free survival (PFS) in the study, and improved outcomes compared to the current standard of care. ... treatment. In the phase 3 ATTRACTION-3 trial, which evaluated
First worldwide approval for MET inhibitor. Japan’s medicines regulator has approved Merck KGaA’s oral MET inhibitor tepotinib for non-small cell lung cancer with MET exon 14 (METex14) mutations, ... The Japanese approval is the first worldwide for
The reformulation could open up a new and very large treatment category for the drug, as well as new territory for the JAK inhibitor class. ... The oral JAK inhibitor market is split between drugs used to treat cancer, like Jakafi, and those used for
FDA starts priority review of Swiss pharma's MET inhibitor. Novartis’ MET inhibitor capmatinib could be approved for marketing in the US within six months for a rare form of ... The start of the review puts Novartis in a position to bring a drug for MET
It seems like that sacrifice was worth it, with cabozantinib in combination with PD-1 inhibitor Tecentriq (atezolizumab) hitting the primary endpoint of an improved objective response rate. ... Cabozantinib, a c-MET and VEGFR2 inhibitor, is already
The deal – due to close in the first quarter of 2020 – will give Merck ownership of ARQ 531, a BTK inhibitor that has just reported more encouraging data in B-cell ... trials, with recent fails including c-MET inhibitor tivantinib.
More from news
Approximately 2 fully matching, plus 31 partially matching documents found.
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...